Toggle Health Problems and D

53 Multiple Sclerosis patients somewhat helped by 10,000 IU of vitamin D (vs, 30,000 virtually cured by 10X as much) – Jan 2020

High-dose vitamin D supplementation in multiple sclerosis – results from the randomized EVIDIMS (efficacy of vitamin D supplementation in multiple sclerosis) trial

J Multiple Sclerosis Journal – Experimental, Translational and Clinical, https://doi.org/10.1177/2055217320903474
an Dörr*†, Priscilla Bäcker-Koduah*, Klaus-Dieter Wernecke, ...


This EVIDIMS Randomized Controlled trial used 20,400 IU of Vitamin D every second day
Some success was achieved (see table below)

Dr. Coimbra's protocol customizes the treatment for each MS patient
   Thus it cannot be run as a Randomized Controlled Trial
Vitamin D is not a single magic bullet - many other nutrients are used
One (dose) size does not fit all - The Coimbra Protocol uses 2X to 15X as much vitamin D

MS References in VitaminDWiki – Dec 2019

UV and Sunshine reduces MS risk

Other things also help

High Dose Vitamin D and cofactors

Number of MS studies which are also in other categories

  • 22 studies in Genetics - genes can restrict Vitamin D getting to the blood and to the cells
  • 12 studies in Vitamin D Receptor - gene which restricts D from getting to the cells
  • 7 studies in Vitamin D Binding Protein - gene which restricts D from getting to the cells
  • 21 studies in Ultraviolet light - may be even better than Vitamin D in preventing and treating MS
  • 9 studies in Omega-3 - which helps Vitamin D prevent and treat MS

Table compares 4 High-dose vitamin D therapies


 Download the PDF from VitaminDWiki

Portion of table in the PDF


Epidemiological, preclinical, and non-interventional studies link vitamin D (VD) serum levels and disease activity in multiple sclerosis (MS). It is unclear whether high-dose VD supplementation can be used as an intervention to reduce disease activity.

The study aimed to compare the effects of every other day high- (20,400 IU) versus low-dose (400 IU) cholecalciferol supplementation on clinical and imaging markers of disease activity in patients with relapsing–remitting MS or clinically isolated syndrome.

The EVIDIMS (efficacy of vitamin D supplementation in multiple sclerosis) trial was a multicentre randomized/stratified actively controlled explorative phase 2a pilot trial with a double-blind intervention period of 18 months, add on to interferon-β1b.

Fifty-three patients were randomized, and 41 patients completed the study. Cholecalciferol supplementation was well tolerated and safe in both arms. After 18 months, clinical (relapse rates, disability progression) and radiographical (T2-weighted lesion development, contrast-enhancing lesion development, brain atrophy) did not differ between both treatment arms. Post-study power calculations suggested that the sample size was too low to prove the hypothesis.

The results neither support nor disprove a therapeutic benefit of high-dose VD supplementation but provide a basis for sound sample size estimations in future confirmatory studies. www.clinicaltrials.gov/NCT01440062

Created by admin. Last Modification: Saturday January 25, 2020 12:59:44 GMT-0000 by admin. (Version 8)

Attached files

ID Name Comment Uploaded Size Downloads
13401 EVIDIMS - portion of table.jpg admin 25 Jan, 2020 84.28 Kb 1139
13400 EVIDIMS 20,000 every other day.pdf admin 25 Jan, 2020 509.17 Kb 538